Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves. (3rd June 2018)

• Record Type: Journal Article
• Authors: Andrade, Jason G.; Meseguer, Elena; Didier, Romain; Dussault, Charles; Weitz, Jeffrey I.
• Is Part Of: Expert review of cardiovascular therapy. Volume 16:Number 6(2018)
• Page Start: 413
• Page End: 418
• Publication Date: 2018-06-03
• Subjects: Atrial fibrillation -- bioprosthetic heart valves -- stroke -- anticoagulation; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1080/14779072.2018.1475229
• Languages: English
• ISSNs: 1477-9072

Abstract

ABSTRACT: Introduction : The non-vitamin K antagonist oral anticoagulants (NOACs), which include dabigatran, apixaban, edoxaban and rivaroxaban, are preferred over vitamin K antagonists for stoke prevention in most patients with non-valvular atrial fibrillation. The NOACs are contraindicated in atrial fibrillation patients with rheumatic mitral stenosis or mechanical heart valves. There is evidence that bioprosthetic heart valves are less thrombogenic than mechanical heart valves, but it is unknown whether the risk of thromboembolism in atrial fibrillation patients with bioprosthetic valves differs from that in patients without such valves. Areas covered : The authors present a review of the efficacy and safety evidence surrounding the use of NOACs for stroke prevention in atrial fibrillation patients with bioprosthetic heart valves. Expert commentary : While the data is limited, there is no significant difference in thromboembolic, and bleeding outcomes in patients with AF and bioprosthetic heart valves treated with NOAC therapy. Future studies are required before definitive conclusions can be drawn regarding the safety and efficacy of NOAC therapy in AF patients bioprosthetic heart valves.